Fulcrum Therapeutics Signs an Exclusive License Agreement with CAMP4 Therapeutics to Advance Novel Therapies for Rare Hematologic Diseases
Shots:
- CAMP4 will receive an up front & ~$70M upon achievement of development, regulatory & commercial milestones along with royalties
- Fulcrum to get an exclusive license right to intellectual property arising from CAMP4’s DBA program, incl. the right to research, develop, manufacture & commercialize the compounds against an undisclosed target for Diamond-Blackfan Anemia
- Fulcrum will lead the research, development, manufacturing & commercialization costs and activities. The agreement will combine Fulcrum’s deep expertise in hematology and small molecule development to advance the discovery and delivery of therapies, strengthens Fulcrum’s discovery pipeline & reinforces the strategy for rare genetic conditions through small molecules
Ref: GlobeNewswire | Image: Fulcrum
Related News:- Fulcrum Seeks to Initiate the P-III (REACH) Trial of Losmapimod for the Treatment of Facioscapulohumeral Muscular Dystrophy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
